Visiomed Group Ltd Ground Floor, 45 Stirling Highway T (08) 9389...

Visiomed Group Ltd Ground Floor, 45 Stirling Highway T (08) 9389 0700 E [email protected]
ABN 34 003 010 580 Nedlands, Western Australia 6009 F (08) 9389 0733 W www.visiomed.com.au
Deliver, comply and Monitor
ASX Release
3 May 2007
Visiomed Appoints US Distributor for Funhaler®
�� Signs Contract with Major Distributor of Respiratory Products in USA
Visiomed Group Ltd (ASX: VSG) is pleased to announce it has signed an
initial 2-Year Agreement with Alliance Tech Medical Inc. to distribute its
innovative Funhaler® paediatric incentive asthma spacer in the United States.
Alliance Tech Medical (ATM) is the pre-eminent distributor of respiratory products
in the US healthcare industry. ATM has four regional headquarters located in
California, Texas, Delaware and Illinois with over 30 direct sales representatives
and a partnership with a nationwide group of distribution outlets. The Company
had set initial target sales of 50,000 units during the preliminary test marketing
period.
“The US is the world’s major market for medical products and is a key market for
Visiomed” said Dr William Dolphin, Visiomed Chief Executive Officer. “With a
population of over 300 million there are an estimated 42 million asthmatics in the
US of which approximately 10 million are under the age of nine.
“During the early stages of market development we will participate in major
conferences and work with key influencers – physicians, respiratory therapists and
asthma support groups - to ensure a high level of acceptance and uptake of the
Funhaler® product.
“ATM’s wide coverage and experienced regional management will provide
Visiomed with high quality access to the US healthcare system, patients and
respiratory specialists. Working with ATM we are confident that we will rapidly
achieve a high level of market penetration,” he said.
Mr John Snobarger, President and CEO of ATM, said: “Alliance Tech Medical Inc.
specializes in providing the North American market with premier products for the
management of respiratory diseases. The Funhaler® meets our criteria for superior
products as it is highly innovative and has clinically demonstrated effectiveness.
We are proud to partner with Visiomed and believe the Funhaler® addresses the
needs of the paediatric and child segment of this large and growing market.”
The Funhaler® is a patented incentive asthma spacer (valved holding chamber)
designed specifically for the paediatric market. Designed to attach to asthma
‘puffers’, the Funhaler® incorporates auditory and visual incentives that encourage
children to more easily and effectively take their asthma medication.
Visiomed has recently completed distribution agreements in South America,
Europe and the Middle East and continues discussions with key distributors in
other major European and Asian markets.
“As we continue to expand our global market presence Visiomed is being
recognized as a significant player in the large and growing respiratory care market.
Recent manufacturing improvements ensure we can deliver the large order
volumes anticipated in the coming months,” Dr Dolphin said.
Visiomed Group Ltd Ground Floor, 45 Stirling Highway T (08) 9389 0700 E [email protected]
ABN 34 003 010 580 Nedlands, Western Australia 6009 F (08) 9389 0733 W www.visiomed.com.au
About Visiomed Group Ltd
Visiomed (www.visiomed.com.au) develops and commercialises innovative medical technologies for
improved medication delivery and adherence in patients suffering from chronic respiratory diseases,
providing the interface between patient and their medication.
Visiomed manufactures and sells a range of spacers for the paediatric, adolescent and adult market
and is the leading provider of spacers in Australia. More than 350 million people suffer from asthma
and COPD (chronic obstructive pulmonary disorder, including chronic bronchitis and emphysema)
and are candidates for the Company’s spacer products.
The Funhaler® paediatric incentive spacer and Breath-A-Tech spacer products are covered by
international patents issued and pending. The coverage extends to protection of a wide range of
alternative incentive modules and complimentary applications. The Funhaler® is CE marked for the
EU, FDA cleared for the US and TGA registered in Australia.
Further Comments:
Dr William Dolphin
CEO Visiomed Group Ltd
P: (08) 9389 0700
M: 0433 145 713
Media Enquiries:
Sarah Allchurch
Allchurch Communications
P: (08) 9381 6625
M: 0412 346 412